Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
BEIJING, Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medical Products Administration of the People's Republic of Chinahas granted approval to the application for the Registration Certificate for Medical Device for the proton therapy equipment (the "Registration Certificate") made by the Company's equipment supplier on December 6, 2024. As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently obtained the large medical equipment procurement license for its proton equipment in September 2024. Upon obtaining the approval for the Registration Certificate, Guangzhou Hospital plans to start its proton therapy treatment services at its earliest convenience after necessary preparations.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more